ZURICH Big U.S. pharmacy chain CVS Health's move to jettison an Actelion drug from a list of covered medications is not expected to have a "meaningful impact" on the Swiss biotechnology company's sales, a spokesman said on Wednesday.
CVS on Tuesday released a list of more than 30 drugs it was removing from its 2017 standard formulary, including Actelion's Opsumit for deadly pulmonary arterial hypertension, or PAH.
02:14 Green Bay Packers expected to cut Sam Shields20
20:41 Jose Bautista to re-sign with Blue Jays with one-year deal7
14:01 Hispanic Dems warn Latinos will be hit hard by ObamaCare repeal20
12:23 Sterling volatile as market speculates on ‘hard Brexit’; investors await May's speech15